On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...

Gilead has said it has begun two phase 3 trials of its potential COVID-19 coronavirus antiviral remdesivir in adults affected by the disease, expanding ongoing research in the US and China. The ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

Since the initial release of Open AI’s Chat GPT in 2022, the adoption of artificial intelligence (AI) technology has spread ...

Since the initial release of Open AI’s Chat GPT in 2022, the adoption of artificial intelligence (AI) technology has spread ...

The most eye-catching project involves sofosbuvir – the active ingredient in Gilead’s hugely successful ... that can bind to the surface of the coronavirus and neutralise it.

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...